Citius Pharmaceuticals Shares Drop 2.3%

Analysts Debate Whether Investors Should Sell the Stock

Mar. 2, 2026 at 11:47pm

Got story updates? Submit your updates here. ›

Shares of Citius Pharmaceuticals (NASDAQ:CTXR) fell 2.3% on Monday, trading as low as $0.70 per share. The biopharmaceutical company, focused on developing critical care products and novel drug delivery systems, saw trading volume decline 76% from its average. Analysts have mixed views on the stock, with one recommending a sell, two a hold, and one a buy rating.

Why it matters

Citius Pharmaceuticals is a clinical-stage company working on treatments for acute care, hospital-acquired infections, and subcutaneous drug delivery. Its stock performance and analyst sentiment can provide insights into investor confidence in the company's pipeline and future prospects.

The details

Citius Pharmaceuticals shares closed at $0.7230 on Monday, down from the previous close of $0.74. Trading volume was 121,010 shares, a 76% decline from the average of 504,491 shares. Analysts have provided a range of ratings on the stock, with Weiss Ratings issuing a 'sell (e+)' recommendation, D. Boral Capital maintaining a 'buy' rating and $6.00 price target, and Wall Street Zen upgrading the stock from 'strong sell' to 'hold'.

  • Citius Pharmaceuticals shares traded down 2.3% on Monday, March 3, 2026.

The players

Citius Pharmaceuticals, Inc.

A clinical-stage specialty pharmaceutical company focused on developing critical care products and novel drug delivery systems. The company is headquartered in Cranford, New Jersey and trades on the NASDAQ under the symbol CTXR.

Weiss Ratings

A financial research and ratings firm that issued a 'sell (e+)' recommendation on Citius Pharmaceuticals shares.

D. Boral Capital

A financial research firm that maintained a 'buy' rating and $6.00 price target on Citius Pharmaceuticals shares.

Wall Street Zen

A financial research firm that upgraded Citius Pharmaceuticals shares from 'strong sell' to 'hold' rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

Citius Pharmaceuticals' stock performance and mixed analyst views reflect the challenges and uncertainties facing the clinical-stage pharmaceutical company as it works to advance its pipeline of critical care and drug delivery products. Investors will be closely watching for updates on the company's progress and any changes in analyst sentiment.